Metastasis-free Survival in High-risk Prostate Cancer: A Valid Surrogate, but Is it Transportable Across Strategies of Unequal Systemic Exposure?
Authors:
- Michael BaboudjianMichael Baboudjian
- Alessandro UleriAUAlessandro Uleri
- Giuseppe FallaraGFGiuseppe Fallara
- Alberto MartiniAMAlberto Martini
- Guillaume PloussardGPGuillaume Ploussard
- 6 October 2026
- journal article
- Published by Elsevier in European Urology Oncology
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- Perioperative Apalutamide in High-Risk Localized Prostate CancerNew England Journal of Medicine, 2026
- Pelvic Lymph Node Dissection in Prostate Cancer: Update from a Randomized Clinical Trial of Limited Versus Extended DissectionEuropean Urology, 2024
- Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate CancerNew England Journal of Medicine, 2023
- Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocolThe Lancet, 2022
- Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre studyThe Lancet, 2020
- Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trialThe Lancet Oncology, 2019
- 20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 YearsNew England Journal of Medicine, 2017
- Metastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate CancerJournal of Clinical Oncology, 2017